Baseline CD335+ iNK-T cells predicted the response to the combination of pomalidomide, ixazomib, clarithromycin, and dexamethasone. Baseline peripheral blood samples (cycle 1 day 1, before treatment) of patients who had at least a VGPR or better (left curve, blue points) were compared with those who had a PR or SD (left curve, red points). Across all time points, deeper responders had lower CD335⁺ iNK T cells. The c-statistics for the AUC was 0.79, which indicates that baseline CD335⁺ iNK T cells were predictive of response to treatment with pomalidomide, ixazomib, clarithromycin, and dexamethasone. AUC, area under the receiver operator curve.